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Abstract  
Background: There are few data comparing patient reported outcomes (PROs) in randomized trials 
of initial antiretroviral therapy (ART). We present results from a substudy of the 
NEAT001/ANRS143 trial. 
Methods:  The randomized trial compared first-line DRV/r 800/100mg once daily plus RAL 
400mg twice daily and DRV/r plus TDF/FTC 245/200mg once daily. Changes in PROs were 
assessed with 3 questionnaires: EuroQoL 5 domains (EQ-5D), Centre for Epidemiologic Studies 
Depression scale (CES-D), and HIV Treatment Satisfaction (HIVTSQ). Major Depressive Disorder 
(MDD) was defined as CES-d≥16. General estimating equations were used to model change over 
96 weeks in PROs from baseline. 
Results: Of the 805 participants, 797(99%) contributed to the substudy. Baseline PROs data were 
similar for the two randomized groups. Health status improved over time with a mean increase in 
EQ-5D visual analogue scale of 8.0 by W96 (95%CI 6.5-9.4; p<0.001), and no statistically 
significant differences between groups (difference of 0.3 on VAS score (95%CI -1.7, 2.3); p=0.7, 
global p-value ≥0.05 for all domains over follow-up). There was no significant difference between 
groups on CES-D (difference of -0.1 (95%CI -1.3, 1.1); p=0.9), or MDD during follow-up, adjusted 
for baseline MDD (OR=0.98, 95%CI 0.82-1.18; p=0.9). RAL+DRV/r group had lower level 
of convenience (p=0.03) and fitted less well into patients’ lifestyle (p=0.007) than the 
TDF/FTC+DRV/r regimen, and was associated with lower tr atment satisfaction (median score: 53 
RAL+DRV/r vs 55 TDF/FTC+DRV/r (p=0.001).  
Conclusion: PROs improved after starting ART, with no statistically significant difference between 
groups. The lower satisfaction with RAL+DRV/r may be explained by twice-daily administration. 
Key words 
Quality of life; raltegravir; treatment satisfaction; EQ5D; ritonavir-boosted darunavir; health 
improvement  
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Introduction 
Antiretroviral therapy (ART) has dramatically reduced mortality and morbidity at all stages of HIV 
infection 1,2, making an overall improvement of patients’ health status an important goal of 
therapy.  In fact, according to most recent guidelines, one of the key treatment goals is to “prolong 
the quality of survival” 3. In this context, patient-reported outcomes (PROs) have been recognized 
as an important measure of health that deserves to be taken into account, together with the 
traditional efficacy and safety parameters, when measuring a patient’s health status both in research 
and clinical practice. Indeed, there is compelling evidence that both HIV infection and prolonged 
ART can impair PROs such as health-related quality of life (HRQL), fatigue, and work productivity 
4. Assessment of PROs measures is of particular inteest when two or more therapeutic strategies 
have the same clinical efficacy, as PROs are the major drivers of adherence to long-term ART 5. In 
fact, PROs during treatment may explain the gap that is frequently reported between efficacy rates 
and those reported for the effectiveness of ART in the real world practices. PROs are also important 
surrogates for patients’ experience with their disease and its treatment 6. Combined, these reasons 
make PROs important endpoints for clinical trials to identify the strategy that maximize the 
patient’s health status, and irreplaceable sources of important information in clinical practice 7. A 
large European NEAT001/ANRS143 randomized multicenter trial which compared two different 
ART regimens for 1st-line treatment in naïve patients showed non-inferiority based on a virological 
composite primary outcome at 96 weeks. There was also no difference in the frequency of serious 
or treatment modifying adverse events. We report the results of a specific PROs’ substudy nested 
within the NEAT001/ANRS143 large clinical trial.  . 
 
Participants and methods 
Study treatment and participants 
NEAT001/ANRS143 was a randomized, open-label, non-iferiority trial conducted in 15 European 
countries between August 2010, and October 2013. The full study design and results have been 
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previously reported 8. Briefly 805 naive HIV-infected adults were randomly assigned in a 1:1 ratio 
to receive oral treatment with 800mg darunavir and 100mg ritonavir once daily plus either 400mg 
raltegravir twice daily (NtRTI-sparing regimen) or tenofovir/emtricitabine in a 245mg and 200mg 
fixed dose combination once daily (standard regimen). Participants were offered to participate in the 
PROs’ substudy. Ethics committee approval was obtained for all participating centers, in 
accordance with the principles of the Declaration of Helsinki. All trial participants gave written 
informed consent. The study was registered with ClinicalTrials.gov (NCT01066962). 
 
Data collection 
Participants attended study centers at screening, baseline (randomization), weeks 2, 4, 8, 12, 18, 24, 
32, 48, 64, 80, and 96, and every 12-16 weeks thereaft . Each visit included assessment of vital 
signs and adverse events, physical examination, and collection of blood samples for full blood cell 
counts and serum chemistry, liver function and immuno-virological measurements, except at W2 
for the latter. Adverse events recorded during the s udy were grouped based on the body system as 
previously described 8.
 
Patient-reported outcomes 
PROs were collected at baseline and during scheduled follow up visits at weeks 4, 12, 24, 48 and 96 
through self-administered questionnaires in participants’ native languages. Four PROs 
questionnaires were used in this study: 1) The EuroQoL 5 domains (EQ-5D) 9, a widely used 
generic questionnaire for measuring health related quality of life (HRQoL), that includes two parts. 
The EQ-5D self-classifier asks participants to describe their health on five domains: (mobility, self-
care, usual activities, pain/discomfort, and anxiety/depression) and three levels: 1 indicating ‘‘no 
problem,’’ 2 indicating ‘‘some or moderate problems,’’ and 3 indicating ‘‘extreme 
problems/impossible to do.’’ The EQ-VAS is a visual analogue scale that takes values between 100 
(best imaginable health) and 0 (worst imaginable healt ) on which participants provide an overall 
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measure of their health status; 2) The ISS-NEAT HIV Symptoms scale, a self- administered list of 
38 symptoms 10, that evaluates the impact of symptoms over the last 4 weeks through a Likert five-
point intensity scale rated from ‘not at all’=1 to ‘a very great deal’=5; 3) The Center for 
Epidemiological Studies-Depression (CES-D), that asks participants to rate how often over the past 
week they experienced symptoms associated with depression, with response options ranging from 0 
to 3 for each item (0 = rarely or none of the time, 1 = some or little of the time, 2 = occasionally or 
moderately, 3 = most or all the time). Major Depressive Disorder (MDD) was defined as CES-D 
≥16. In this study a short version of 10 items was used 11; 4) The HIV Treatment Satisfaction 
Questionnaire (HIVTSQ) measuring overall satisfaction with HIV treatment and by specific 
domains such as convenience, ease of use, and flexibility through a 10-item self-reported scale with 
a maximum possible score of 60 12. 
Statistical analysis 
Together with clinico-demographic parameters, the PROs at and during follow-up were compared 
between the 2 trial treatments using Pearson's chi-quare test for categorical variables or t-tests and 
Wilcoxon ranksum tests for continuous variables. The two treatment groups were compared as 
randomized, according to the intention-to-treat principle. Generalised estimating equations (GEEs) 
including all participants that contributed one or more questionnaires were used to model: change 
over time in PROs from baseline; odds of MDD during the trial adjusted for baseline MDD; and 
odds of having moderate or severe problems (compared to no problems) on EQ5D domains adjusted 
for baseline levels. GEEs were used as the models can handle missing measurements without the 
need for imputation and have been shown to be a viable nalysis for PROs in HIV trial data.13 
Within the GEE models, potential differences between arms and visit weeks were accounted for 
with interaction terms. Sensitivity analyses were carried out by imputing missing values of PROs at 
each time point using multiple imputation with chained equations (with predictive mean matching 
for CES-D and EQ-VAS, and regression for HIV symptom score) and then changing the imputed 
values to test the assumption that the group who had missing data had systematically worse or better 
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outcomes14. Baseline factors that were associated with change i  EQ5D VAS scale over time (age, 
gender, country of enrolment, body mass index (BMI), mode of infection, ethnicity, HIV stage, 
CD4 and log10 plasma HIV RNA) were included in the GEE model. Levels of treatment satisfaction 
between groups were compared with chi-squared tests in participants with questionnaires at baseline 
and W96 and logistic regression for the % very satisfied at W96 adjusted for baseline factors. This 
timepoint was in line with the primary endpoint forthe main trial measured once all participants had 
reached W96. For this PROs’ substudy, no predetermin d sample size was calculated. Statistical 
analyses were performed using Stata v14.0. 
 
Results 
Baseline characteristics and data completeness 
Of the 805 participants, 797 (99%) contributed to the substudy: 683/797 (86%) at baseline, 611 
(77%) at W96, 526 (66%) at both visits. A minimum of 74% participants contributed to PRO data at 
each visit and >80% contributed at visits within the first 12 weeks (Figure 1A). There was no 
significant difference between randomized groups for completeness of data at each visit and overall 
(global p-value from GEE models for missingness of CES-D scale, EQ-VAS and HIV symptom 
scale score was 0.10, 0.41, and 0.28 respectively). Baseline characteristics and PROs of the 
participants contributing at baseline were not different between treatment groups (Table 1) and were 
similar to those of the 805 participants randomized to the main NEAT001/ANRS143 trial   
 
PRO measures  
There were no significant differences between randomized groups for any of the EQ-5D domains 
including VAS over time (Table 2 and Figure 1A). During follow-up an improvement of participant 
overall health status (EQ-VAS) was observed in both randomized groups, with a marked increase 
during the first 24 weeks of therapy (difference from baseline of 7.5 (95% CI 6.5,8.5); p<0.001), 
then a plateau, however there were no statistically significant differences between randomized 
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groups at any time point (Figure 1a). A reduction of HIV symptoms scale score was observed in 
first 4 weeks (difference from baseline of -3 (95%CI -4,-2); p<0.001) for standard regimen), with 
stabilisation up to W96 and no statistically significant differences between the two randomized 
groups (Figure 1b). Depression/anxiety as measured on the CES-D scale also improved, as by week 
4, statistically significant improvement was evidenc d in both groups (difference of -3 (95% CI (-
4,-2); p<0.001), with no difference between the 2 groups (Figure 1c). Sensitivity analyses showed 
that under the assumptions that participants with missing PROs either had systematically worse or 
better outcomes there were no significant differences between randomized groups for EQ-VAS, 
CES-D or HIV symptom scale score (Appendix Table 1, http://links.lww.com/QAI/B211). There 
was no evidence of a difference between groups in MDD during the 96 weeks duration of the study 
(OR 0.98, 95% CI 0.82,1.18). At W96, participants in the NtRTI-sparing regimen reported 
significantly lower median score in treatment satisf ction than participants in the standard regimen 
(53 (IQR 48-58) versus 55 (IQR 50-59); Kruskel-Wallis p=0.001). There were no differences 
between groups on satisfaction regarding general satisfaction, satisfaction with control and 
understanding of disease, side effects, or wish to continue current treatment (Table 3).  
PROs predictors 
Age (Wald test p<0.001) and country of enrolment (overall Wald test p=0.05) were found to be 
independently associated with change in overall healt  status adjusting for the other baseline factors 
and baseline EQ5D VAS. Older age was associated with lower VAS score (decrease of -0.1 (95% 
CI -0.2,-0.05) per age year), and two countries were associated with increased VAS score (Hungary 
(n=6, increase of 11 (95% CI 1,21); p=0.03), and Portugal (n=21, increase of 12 (95%CI 3,21); 
p=0.007). The potential baseline predictors were also included in the models for change in CES-d 
and HIV symptoms scale adjusted for their baseline values. Age was found to be an independent 
predictor of change in the model for HIV symptoms scale with older age associated with an 
increased score (increase of 0.1 per age year (95%CI 0.03,0.2); p=0.006). Gender was found to be 
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an independent predictor of change in CES-d score with female gender (including transgender male 
to female) associated with an increased CES-d score (increase of 2 (95% CI 0.1,4); p=0.04).  
 
Multivariate analysis of treatment satisfaction 
A logistic regression model was fitted for the proportion who responded with 5 or 6 (very satisfied) 
on each question on the HIVTSQ at W96 adjusted for treatment group, age at enrolment, gender 
and change from baseline in the other PRO measures (CES-d, EQ5D VAS and HIV symptom 
score). The proportion of participants feeling very satisfied with convenience, extent with which 
treatment fits into their lifestyle and who would recommend their treatment to a friend were higher 
in the standard regimen after adjustment (Table 3).  
 
Discussion 
Our data indicate that the majority of PRO domain scores measured with 4 different validated 
instruments significantly improved during 1St line antiretroviral treatment. Previous studies have 
shown reduction of fatigue and HIV symptoms in HIV-infected patients initiating antiretroviral 
therapy 15,16 but few studies have evaluated PROs in a randomized comparative study. 
In our study, improvement of PROs scores started shortly after the initiation of therapy and then 
plateaued between 6 months and 2 years on continuous therapy, suggesting that PROs benefit was 
maximal when plasma virologic suppression was achieved and did not increase thereafter. For three 
of the PRO measures assessed, HRQoL, HIV symptoms scale and CES-D, improvement was not 
different between the two randomized groups either ov rall or any time point of follow-up. These 
results represent additive arguments to the hypothesis that PROs improvement is related to virologic 
suppression achievement rather than to a specific drug regimen. However, it is interesting to note 
that PROs improvement in the first weeks after treatm nt initiation were of similar magnitude in 
both randomized groups, although at W4 and W24 a significantly higher proportion of participants 
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achieved virologic suppression on the NtRTI regimen, while at 96 weeks both regimens were 
virologically non-inferior 8. The underlying mechanisms to connect HIV plasma suppression with 
PROs improvement are yet to be elucidated 17. Some putative mechanisms may be related to the 
improvement of cytokine and other metabolites profile, both in peripheral blood and central nervous 
system, due to the viral suppression which could in tur  positively impact patients’ experience 18. 
Viral suppression might thus improve fatigue and other PROs related to chronic HIV infection 19.  
Our multivariate analysis showed an association betwe n older age and lower health-related 
outcomes. Poorer PROs in older patients has been reported in many studies on HCV treatment, 
including the most-recent ones with highly effective and very well tolerated direct-acting antiviral 
regimens 20. Older age was negatively associated with physical Fatigue Impact Scale subscores in 
an observational study on raltegravir 19, while in a review of literature, there was no association 
between age and fatigue in most studies 21. HIV disease factors, such as CDC stage, CD4 and 
plasma HIV RNA did not influence PROs improvement, i dicating that benefit of HIV therapy on 
quality of life was seen whatever the baseline immune-virological status of the patient, taking into 
account that 15 patients in our study had CD4 cell counts< 200/mm3 and only 5% CDC stage C 
HIV infection. 
Association of worsening of depression score in women over time might be related to higher 
difficulty to cope with HIV disease or to higher vulnerability or perceived stigma. Most studies in 
an HIV-positive population have showed a higher rate of depression in women than men 22, 
however no longitudinal study over a 2-years period has been reported.  The difference found in 
improved overall health status by country, as measured by EQ-VAS score, was driven by 
differences in Hungary and Portugal, and could be due to the small numbers enrolled in the trial in 
these countries as modest absolute differences from baseline in small groups can have a large 
impact. HIVTSQ scores for treatment convenience, fitting into lifestyle and willingness to 
recommend to a friend were significantly higher in participants taking the 3 pills once daily DRV/r 
+ TDF/FTC regimen compared to 4 pills DRV/r + RAL regimen requiring twice daily intake, 
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possibly reflecting a preference for a simplified rgimens with less daily intake. A meta-analysis of 
randomized clinical trials has shown that lower pill burden was associated with both better 
adherence and virological suppression 23. However, once-daily regimens were associated with 
slightly better adherence, but not virological suppression, as compared with twice-daily regimens 23. 
Absence of differences in satisfaction with regards to ide effects and HIV disease control and 
knowledge between randomized groups is in line withfindings of the study showing non-inferiority 
of virological efficacy and no differences in safety over follow-up 8. In fact, even if participants 
were less satisfied with twice-daily regimens and less prone to recommend such a regimen, this did 
not translate in poorer outcome at W96.  Indeed, the finding of a 2-point difference in treatment 
satisfaction score, although statistically significant, did not seem to have much clinical relevance 
since it did not appear to be associated with any adverse patient-reported or clinical outcomes. 
Furthermore, participants on twice-daily DRV/r + RAL regimen were equally satisfied to continue 
on their current regimen than those on once-daily DRV/r + TDF/FTC, probably because of 
perceived benefit in terms of virologic suppression and immunologic recovery. 
 
The study limitations primarily arise from the nature of any clinical trial study which has strict 
enrollment criteria and close follow-up. In this context, the findings from an efficacy trial may 
potentially have limited generalizability to the entire HIV population. However, the design of our 
study was pragmatic with a wide range of enrolment criteria and similar follow-up to routine care. 
Additionally, some parameters which could potentially be associated with PROs were not collected 
during the study. These include level of education, marital status, income, and type of work. 
Finally, some of the PRO instruments were not systema ically validated in all languages used in this 
study. Nevertheless, all these instruments have been systematically translated with some face-to-
face and content validation. We also acknowledge that EQ5D might lack sensitivity, and may not 
capture subtle differences in participants’ quality of life. 
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In summary, this randomized-controlled trial of twice daily DRV/r + RAL versus once daily DRV/r 
+ TDF/FTC demonstrated significant and persistent improvement of PRO scores during treatment. 
PROs improve rapidly after treatment initiation, with no difference between arms, reflecting 
probable improvement in immuno-virologic status and/or suggestive perception of disease control 
while on therapy. However treatment satisfaction was significantly lower with the twice-daily 
regimen for convenience and fitting into the participants’ lifestyles, without affecting W96 
outcome. These findings provide a comprehensive appro ch when treating and selecting initial ART 
in HIV-infected participants.  
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Table 1: Baseline patient reported outcomes and characteristics 
Patient Reported Outcomes 
RAL + DRV/r 
 
TDF/FTC + DRV/r 
 
Median (IQR) CES-d score ; N 12 (7, 18); 328 12 (7, 19); 332 
Major Depressive Disorder (MDD) (%) 121/328 (37%) 110/332 (33%) 
Median (IQR) HIV Symptom scale ; N 49 (43, 59); 331 49 (42, 59); 337 
Euroqol EQ5D domains (% moderate or severe problems) 
  Mobility  11/335 (3%) 11/342 (3%) 
  Self-care  2/335 (<1%) 5/341 (1%) 
  Usual Activities  26/336 (8%) 26/340 (8%) 
  Pain/Discomfort 79/335 (24%) 90/341 (26%) 
  Anxiety/Depression 143/336 (43%) 145/340 (43%) 
Median (IQR) EQ5D VAS; N 80 (70-90); 319 80 (70-90); 327 
Baseline characteristics for those with any baseline PRO 
recorded 
N=340 N=343 
Mean (sd) Age (years)  38 (10) 39 (10) 
Male (%) 299 (88%) 305 (89%) 
Mean (sd) baseline CD4 (mm3) 328 (7) 315 (7) 
Mean (sd) baseline HIV RNA (log10 c/mL) 10.9 (0.08) 10.8 (0.08) 
Mean (sd) BMI (kg/m2 ) 23.8 (0.2) 23.7 (0.2) 
Mode of contamination* 
    Homosexual/bisexual sex 
    Heterosexual sex 
    Intravenous blood use 
    Blood or blood product receipt 
 
230 (72%) 
81 (25%) 
7 (2%) 
1 (<1%) 
 
235 (71%) 
83 (25%) 
10 (3%) 
0 (0%) 
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   Other  3 (1%) 4 (1%) 
Ethnic origin 
   White 
   Black 
   Asian 
   Other 
 
281 (83%) 
43 (13%) 
6 (2%) 
10 (3%) 
 
284 (83%) 
36 (11%) 
8 (2%) 
15 (4%) 
HIV Stage 
     A 
     B 
     C 
 
279 (82%) 
44 (13%) 
17 (5%) 
 
284 (83%) 
43 (13%) 
18 (5%) 
 
*Percentages are based only on patients with available data (RAL+DRV/r n=318, TDF-FTC+DRV/r n=329); 
seven patients had more than one risk factor (RAL+DRV/r n=4, TDF–FTC+DRV/r n=3). There was no 
evidence of differences in any baseline characteristic or PRO between the randomised arms in those that 
had any baseline PRO recorded. 
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Table 2: Odds ratios of RAL+DRV/r vs TDF/FTC+DRV/r for having moderate or severe problems in the 
EQ5D domains over follow up.  
  Odds Ratio of RAL + DRV/r vs TDF/FTC + DRV/r (95% CI)   
EQ-5D Domain W4 W12 W24 W48 W96 
Global 
p-value 
Mobility 
(n=677) 
0.77 
(0.32-1.90) 
0.52 
(0.20-1.36) 
4.18 
(1.12-15.66) 
2.19 
(0.83-5.82) 
2.41 
(0.97-5.96) 
0.05 
Self-care 
(n=677) 
1.26 
(0.15-10.93) 
0.49 
(0.13-1.92) 
0.71 
(0.05-9.51) 
0.26 
(0.03-2.63) 
0.24 
(0.02-2.35) 0.80 
Usual activity 
(n=676) 
0.99 
(0.47-2.07) 
0.98 
(0.45-2.11) 
0.98 
(0.43-2.24) 
0.77 
(0.35-1.66) 
0.75 
(0.33-1.68) 0.99 
Pain or 
discomfort 
(n=676) 
0.74 
(0.48-1.16) 
1.13 
(0.72-1.79) 
1.63 
(1.01-2.64) 
0.96 
(0.60-1.52) 
1.12 
(0.69-1.82) 0.26 
Anxiety or 
depression 
(n=676) 
1.09 
(0.72-1.67) 
1.14 
(0.74-1.74) 
0.87 
(0.57-1.34) 
1.10 
(0.71-1.69) 
1.33 
(0.84-2.10) 0.85 
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Table 3: Odds ratios of RAL+DRV/r vs TDF/FTC+DRV/r for proportion with a ‘very satisfied’ response on the HIVTSQ at W96 and impact of adjusting for potential 
confounders by logistic regression  
Treatment satisfaction Question 
at W96 
(% very satisfied (5 or 6)) 
RAL+DRV/r 
TDF/FTC + 
DRV/r 
Unadjusted OR 
(95% CI) for RAL vs 
TDF/FTC 
Adjusted OR* Other significant factors in model (OR (95%CI)) 
Satisfied with current treatment 
238/268 (89%) 269/288 (93%) 
1.78 (0.98, 3.25); 
p=0.06 
1.55 (0.75, 3.19); 
p=0.24 
Age (1.03 (95%CI 1.0-1.08)) 
Satisfaction with how well HIV 
was controlled  250/268 (93%) 277/287 (97%) 
1.99 (0.90, 4.40); 
p=0.09 
1.99 (0.77, 5.18); 
p=0.16 
HIV symptom score change from baseline (0.92 
(95% CI 0.89-0.96)), and EQ5D VAS change 
from baseline (1.03 (95%CI 1.00-1.06)), 
Satisfied with extent of 
unwanted side effects 234/267 (88%) 250/287 (87%) 
0.95 (0.58, 1.57); 
p=0.85 
0.88 (0.48, 1.60); 
p=0.67 
HIV symptom score change from baseline  
(0.96 (95%CI 0.94-0.99)) 
Satisfaction with how 
demanding  treatment is 180/267 (67%) 220/286 (77%) 
1.61 (1.11, 2.34); 
p=0.01 
1.43 (0.91, 2.24); 
p=0.12 
HIV symptom score change from baseline (0.98 
(95%CI 0.95-1.00)), age (1.03 (95%CI 1.00-
1.05)) and gender (2.72 (95%CI 1.03-7.18)) 
Convenience 
209/268 (78%) 249/287 (87%) 
1.84 (1.18, 2.89); 
p=0.007 
1.86 (0.08, 3.23); 
p=0.03 
HIV symptom score change from baseline 
(0.96 (95%CI 0.94-0.99) 
Flexibility of treatment 
176/271 (65%) 217/285 (76%) 
1.72 (1.19, 2.49); 
p=0.004 
1.54 (0.99, 2.38); 
p=0.06 
CES-d score change from baseline (0.96 
(95%CI 0.93-0.98)), age (1.02 (95%CI 1.00-
1.05)), gender (3.44 (95%CI 1.30-9.10)) 
Satisfaction with understanding 
of HIV 
232/266 (87%) 252/287 (88%) 
1.05 (0.64, 1.74); 
p=0.84 
1.08 (0.60, 1.94); 
p=0.78 
 
Extent with which treatment 
fits into lifestyle  
203/264 (77%) 250/287 (87%) 
2.03 (1.29, 3.17); 
p=0.002 
2.12 (1.22, 3.66); 
p=0.007 
 
Recommendation to a friend 
230/266 (86%) 267/288 (93%) 
1.99 (1.13, 3.51); 
p=0.02 
2.21 (1.09, 4.51); 
p=0.03 
 
Continuation of treatment  
230/266 (86%) 252/286 (88%) 
1.16 (0.70, 1.92); 
p=0.56 
1.43 (0.77, 2.63); 
p=0.26 
EQ5D VAS score change from baseline (0.97 
(95%CI 0.95-0.99)), CES-d score change from 
baseline (0.95 (95%CI 0.91-0.99)). 
*adjusted for change from baseline in CES-d, Symptom scale and EQ5D VAS and baseline factors: age (years), and gender (transgender male to female = 
female, odds ratios estimated for female vs male). 
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a) b)
c)
NB: Global p-value for difference between trial arms over time from randomization.
Number (%) HL visual 
scale completed W0 W4 W12 W24 W48 W96
RAL+DRV/r (n=398) 319 (80%) 318 (80%) 322 (81%) 313 (79%) 320 (80%) 293 (74%)
TDF/FTC+DRV/r (n=399) 327 (82%) 325 (81%) 314 (79%) 322 (81%) 336 (84%) 302 (76%)
Number (%) CES-d scale 
completed W0 W4 W12 W24 W48 W96
RAL+DRV/r (n=398) 328 (82%) 320 (80%) 321 (81%) 311 (78%) 315 (79%) 287 (72%)
TDF/FTC+DRV/r (n=399) 332 (83%) 330 (83%) 321 (81%) 314 (79%) 333 (83%) 305 (76%)
Number (%) HIV SS scale 
completed W0 W4 W12 W24 W48 W96
RAL+DRV/r (n=398) 331 (83%) 325 (82%) 319 (80%) 312 (78%) 323 (81%) 288 (72%)
TDF/FTC+DRV/r (n=399) 337 (84%) 331 (83%) 319 (80%) 315 (79%) 336 (84%) 304 (76%)
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